Checkpoint blockade immunotherapy doubles survival for melanoma brain metastases patients

Written by Jade Parker, Editor

A team of researchers from Brigham and Women’s Hospital (MA, USA) have demonstrated that checkpoint blockade immunotherapy (CBI) provides a significant improvement in overall survival for patients with melanoma brain metastases. The findings were recently published in Cancer Immunology Research. “Our findings build on the revolutionary success of CBI clinical trials for advanced melanoma and demonstrate that their substantial survival benefits also extend to melanoma patients with brain metastases,” stated corresponding author J. Bryan Iorgulescu, from Brigham and Women’s Hospital/Harvard Medical School and the Dana-Farber Cancer Institute (both MA, USA). As early clinical trials of CBIs and BRAFV600-targeted therapy either excluded...

To view this content, please register now for access

It's completely free